Indian Journal of Medical Specialities

REVIEW ARTICLE
Year
: 2022  |  Volume : 13  |  Issue : 4  |  Page : 211--215

Naltrexone beyond psychiatric domain


Ashutosh Garg, Khyati Thapliyal, Vivek Pal Singh 
 Department of Internal Medicine, BLK-Max Super Speciality Hospital, New Delhi, India

Correspondence Address:
Dr. Vivek Pal Singh
Department of Internal Medicine, BLK-Max Super Speciality Hospital, New Delhi
India

Naltrexone, an opioid receptor (OR) antagonist, at its standard doses, is a United States Federal Drug Administration-approved drug for opioid and alcohol use disorders. However, with the discovery of nonneuropsychiatric effects of OR signaling with low-dose naltrexone, it has found novel applications in inflammatory, malignant, insulin sensitivity-related, and chronic pain conditions. Lower doses also ameliorate its adverse effects. Its off-label use in the abovementioned situations has proven to be cost-effective against costly immunomodulating and antineoplastic drugs. Its lower cost and miniscule margin of interest have precluded in-depth analysis by the pharmaceutical industry. So far, only animal studies, cell culture studies, and case reports have been conducted, some of which exhibit promising benefits. There is a dearth of much-needed quality trials.


How to cite this article:
Garg A, Thapliyal K, Singh VP. Naltrexone beyond psychiatric domain.Indian J Med Spec 2022;13:211-215


How to cite this URL:
Garg A, Thapliyal K, Singh VP. Naltrexone beyond psychiatric domain. Indian J Med Spec [serial online] 2022 [cited 2022 Dec 9 ];13:211-215
Available from: http://www.ijms.in/article.asp?issn=0976-2884;year=2022;volume=13;issue=4;spage=211;epage=215;aulast=Garg;type=0